Market open
ImmunoPrecise Antibodies/$IPA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
Ticker
$IPA
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Victoria, Canada
Employees
87
Website
IPA Metrics
BasicAdvanced
$19M
-
-$0.72
0.19
-
Price and volume
Market cap
$19M
Beta
0.19
52-week high
$2.60
52-week low
$0.32
Average daily volume
12M
Financial strength
Current ratio
1.007
Quick ratio
0.712
Long term debt to equity
35.71
Total debt to equity
50.259
Interest coverage (TTM)
-114.12%
Management effectiveness
Return on assets (TTM)
-13.68%
Return on equity (TTM)
-65.88%
Valuation
Price to revenue (TTM)
0.925
Price to book
0.53
Price to tangible book (TTM)
9.97
Price to free cash flow (TTM)
-2.465
Growth
Revenue change (TTM)
6.36%
Earnings per share change (TTM)
65.61%
3-year revenue growth (CAGR)
8.77%
3-year earnings per share growth (CAGR)
9.75%
What the Analysts think about IPA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ImmunoPrecise Antibodies stock.
IPA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
IPA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
IPA News
AllArticlesVideos
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture
Business Wire·4 hours ago
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment
Business Wire·5 days ago
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ImmunoPrecise Antibodies stock?
ImmunoPrecise Antibodies (IPA) has a market cap of $19M as of January 27, 2025.
What is the P/E ratio for ImmunoPrecise Antibodies stock?
The price to earnings (P/E) ratio for ImmunoPrecise Antibodies (IPA) stock is 0 as of January 27, 2025.
Does ImmunoPrecise Antibodies stock pay dividends?
No, ImmunoPrecise Antibodies (IPA) stock does not pay dividends to its shareholders as of January 27, 2025.
When is the next ImmunoPrecise Antibodies dividend payment date?
ImmunoPrecise Antibodies (IPA) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies (IPA) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.